Multi-Agonism's Ceiling: Do More Receptors Mean More?

Multi-Agonism

6% → 15% → 21% → 24% Weight Loss Trajectory

From liraglutide (single) to semaglutide (single) to tirzepatide (dual) to retatrutide (triple), each added receptor target increased peak weight loss. But the increments are shrinking.

Jastreboff et al., NEJM, 2023

Jastreboff et al., NEJM, 2023

View as image

Each generation of obesity peptide drug has added a receptor target and delivered more weight loss. Liraglutide (GLP-1 only) produced about 6-8% weight loss. Semaglutide (GLP-1 only, higher potency) reached 15%. Tirzepatide (GLP-1 plus GIP) pushed to 21%. Retatrutide (GLP-1 plus GIP plus glucagon) achieved 24.2% in a Phase 2 trial.^[1] The pattern is clear: more receptor targets, more weight loss. But the pattern also reveals something less discussed. The increment from single to dual agonism was roughly 6 percentage points. From dual to triple, the added gain was approximately 3 points. The curve is bending. This article examines where multi-agonism's returns begin to diminish, what limits further escalation, and whether the field is approaching a pharmacological ceiling. For how individual multi-agonists work, see Dual vs Triple Agonist Peptides: Is More Always Better?, More Receptors, More Weight Loss? The Science Behind Multi-Agonism, and Single Molecule vs Combination Therapy: Two Approaches to Multi-Target Treatment.

The Escalation Ladder: From One Receptor to Three

Single agonism: semaglutide sets the benchmark

Semaglutide at 2.4 mg weekly, the most potent approved single-target GLP-1R agonist, produced approximately 15% mean weight loss in the STEP clinical trial program. Amaro et al. synthesized data across multiple STEP trials, documenting consistent effects across populations with and without type 2 diabetes.^[2]

This 15% benchmark was considered transformative in 2021. It roughly doubled the efficacy of liraglutide 3.0 mg (6-8% weight loss), which itself had been the standard since 2014. Both drugs act exclusively through GLP-1R activation, reducing appetite via hypothalamic circuits and slowing gastric emptying. The difference between them is pharmacokinetic optimization: semaglutide's albumin-binding fatty acid chain and structural modifications give it a longer half-life and higher receptor occupancy. For how semaglutide works in non-diabetic populations, see Semaglutide for Weight Loss Without Diabetes: What the Research Says.

Dual agonism: tirzepatide adds GIP

Tirzepatide simultaneously activates GLP-1R and glucose-dependent insulinotropic polypeptide receptor (GIPR). In the SURMOUNT-1 trial, the highest dose (15 mg weekly) produced 20.9% mean weight loss over 72 weeks in people with obesity but without diabetes.^[3] Garvey et al. confirmed similar efficacy in people with type 2 diabetes in SURMOUNT-2, with 14.7% weight loss at the 15 mg dose over 72 weeks.^[4]

The jump from 15% (semaglutide) to 21% (tirzepatide) is approximately 6 percentage points of additional weight loss, attributable to GIP receptor engagement. GIP's contribution to weight loss was initially paradoxical because GIP was historically associated with fat storage. The current understanding is that pharmacological GIPR activation at supraphysiological levels produces different effects from physiological GIP signaling, potentially through GIPR desensitization in adipose tissue or through central nervous system pathways that enhance GLP-1R-mediated satiety.

Dual agonism with glucagon: survodutide takes a different path

Survodutide chose a different second receptor. Instead of GIP, it pairs GLP-1R with glucagon receptor (GCGR) activation. In a Phase 2 obesity trial, survodutide achieved 14.9% weight loss at the highest dose over 46 weeks, a shorter treatment duration than SURMOUNT-1's 72 weeks.^[5]

Thomas et al. documented how survodutide was engineered for balanced dual receptor activation, with the glucagon component driving hepatic fat oxidation and increased energy expenditure rather than appetite suppression alone.^[6] Bluher et al. showed that survodutide outperformed semaglutide for weight loss in a head-to-head comparison in people with type 2 diabetes, with survodutide at 1.8 mg/week or above producing greater bodyweight reductions than semaglutide over 16 weeks.^[7]

Survodutide's 14.9% weight loss, despite activating a second receptor system, falls below tirzepatide's 20.9%. This comparison, though indirect across trials, raises an important point: not all second receptors contribute equally to weight loss. The specific receptor pairing matters as much as the number of targets. For a deep dive on survodutide specifically, see Survodutide: The GLP-1/Glucagon Agonist Targeting Your Liver.

Triple agonism: retatrutide combines all three

Retatrutide (LY3437943) activates GLP-1R, GIPR, and GCGR simultaneously. Jastreboff et al. reported the Phase 2 results in the New England Journal of Medicine: mean body weight decreased by 24.2% at the 12 mg dose over 48 weeks.^[1] Urva et al. had previously established the Phase 1b safety and pharmacokinetic profile, demonstrating dose-dependent metabolic effects across the three receptor axes.^[8]

Rosenstock et al. tested retatrutide in people with type 2 diabetes, finding 16.9% weight loss and substantial HbA1c reductions over 36 weeks.^[9] Phase 3 data reported in 2025-2026 has been even stronger, with the TRIUMPH-4 trial showing up to 28.7% weight loss at the 12 mg dose.

Where the Curve Bends

The data above reveals a clear pattern of diminishing returns:

Each added receptor produces a smaller incremental gain. The 7-9 point jump from liraglutide to semaglutide was achieved within the same receptor by pharmacokinetic optimization. The GIP addition added about 6 points. The glucagon addition added about 3 points in cross-trial comparisons.

This diminishing pattern has three probable explanations.

Appetite suppression has a floor

GLP-1R activation produces dose-dependent appetite suppression, but food intake cannot decrease indefinitely. At some point, caloric intake reaches a physiological minimum below which the body's homeostatic defenses resist further reduction. The additional receptors may be pushing against this floor rather than finding new pathways to reduce intake.

Energy expenditure has limited upside

Glucagon receptor activation increases energy expenditure, but the magnitude of this increase in humans is modest compared to the caloric deficit from appetite suppression. Thomas et al. documented that survodutide increased hepatic NNMT expression by 15-17 fold and FGF21 by sevenfold in preclinical models, but translating preclinical energy expenditure increases to meaningful human weight loss is difficult.^[6]

Tolerability caps dose escalation

Higher multi-agonist doses produce more weight loss but also more gastrointestinal adverse events. Retatrutide's 12 mg dose caused nausea in 26%, diarrhea in 22%, and vomiting in 17% of participants, leading to 12-18% discontinuation rates at the two highest doses.^[1] If tolerability limits prevent further dose escalation, the practical ceiling of multi-agonism may be determined by side effects rather than pharmacology.

The Network Meta-Analysis Perspective

Sinha et al. published a Bayesian network meta-analysis in 2025 that provides the most rigorous indirect comparison across mono-, dual-, and triple-agonist approaches. Analyzing data from adults with overweight or obesity, the study found that retatrutide and dual agonists achieved equivalent mean weight reductions of approximately 11 kg compared to placebo. However, retatrutide was superior for achieving weight loss of at least 15% (odds ratio: 54.6).^[10]

This finding introduces an important nuance. While mean weight loss may plateau across multi-agonist classes, the proportion of patients achieving clinically significant thresholds (15%, 20%, 25% weight loss) continues to increase with more receptor targets. The average patient may not lose much more weight, but more patients cross the thresholds that correlate with resolution of metabolic comorbidities.

The GIP Paradox and the Glucagon Question

The multi-agonism story is complicated by unresolved biology.

Does GIP help or hinder?

GIP was historically classified as an adiposity-promoting hormone. Tirzepatide's success with GIP activation was unexpected and still incompletely explained. Competing hypotheses include: (1) pharmacological GIPR activation desensitizes the receptor, producing a functional antagonism effect on fat storage; (2) central GIP signaling enhances satiety through brain pathways distinct from GLP-1; (3) GIP-mediated insulin secretion prevents the hyperglycemia that would otherwise occur with glucagon co-agonism. If the mechanism is not yet fully understood for dual agonism, predicting what a fourth receptor target would add is largely speculative.

The glucagon trade-off

Adding glucagon activation brings metabolic benefits (fat oxidation, energy expenditure) but also metabolic risks. Glucagon stimulates gluconeogenesis and glycogenolysis, potentially raising blood sugar. In survodutide, the GLP-1 component counterbalances this effect. In retatrutide, both GLP-1 and GIP provide glycemic coverage. But at sufficiently high glucagon receptor engagement, the hyperglycemic pressure could outstrip the insulinotropic effects of GLP-1 and GIP, creating a pharmacological ceiling specific to the glucagon axis.

Beyond Weight: Different Ceilings for Different Outcomes

The diminishing returns question changes when the outcome changes.

For MASH, survodutide's glucagon component may provide outsized benefit despite modest weight loss numbers. Survodutide achieved 62% MASH improvement in Phase 2, a rate that appears competitive with or superior to drugs producing much greater weight loss. The glucagon receptor's direct hepatic effects on fat oxidation represent a pharmacological pathway with a different ceiling than appetite-mediated weight loss. For the liver-specific data, see Retatrutide and Liver Fat: The Surprising MASH Connection.

For cardiovascular outcomes, the relationship between weight loss magnitude and cardiovascular benefit may also plateau. The SELECT trial showed cardiovascular risk reduction with semaglutide at approximately 15% weight loss. Whether 24% weight loss from a triple agonist produces proportionally more cardiovascular benefit is being tested in ongoing trials but is not established. For the cardiovascular evidence landscape, see GLP-1 Drugs and Heart Disease: What the Cardiovascular Trials Show.

For muscle preservation, the ceiling problem inverts. Greater weight loss comes with greater lean mass loss. Semaglutide's 15% weight loss includes approximately 40% lean mass loss. Whether triple agonists worsen this ratio or the glucagon component's protein catabolic effects compound the problem is a critical unanswered question. See GLP-1 Weight Loss and Sarcopenia: The Hidden Risk in Older Adults.

The Safety Escalation: More Targets, More Side Effects

The diminishing efficacy returns are accompanied by escalating safety signals. This creates a widening gap between what each new receptor target adds therapeutically and what it costs in tolerability.

Gastrointestinal adverse events across classes

The table reveals a non-linear pattern. Tirzepatide actually produced lower nausea rates than semaglutide despite achieving more weight loss, suggesting that GIP co-agonism may mitigate rather than compound GLP-1-related GI effects. Survodutide, by contrast, had the highest nausea and vomiting rates, likely because glucagon receptor activation adds its own GI burden. Retatrutide's nausea rate was moderate (26%), but its discontinuation rate at the highest doses (12-18%) reflects the cumulative burden of three receptor targets operating simultaneously.

Heart rate concerns

An emerging signal across multi-agonist classes is increased resting heart rate. GLP-1R activation produces modest heart rate increases (1-4 bpm with semaglutide). Tirzepatide produced similar increases. Early data for retatrutide suggested heart rate increases that exceeded what would be expected from GLP-1R mono-agonism alone, though the short-term nature of early studies limits conclusions about the clinical significance. Whether chronically elevated heart rate from triple agonism carries cardiovascular risk or is a benign pharmacological effect is unknown.

Dose-response within individual drugs

The diminishing returns pattern is also visible within individual drugs, not just across receptor classes. In the retatrutide Phase 2 trial, the jump from 4 mg to 8 mg produced an additional 5.7 percentage points of weight loss (from 17.1% to 22.8%). The jump from 8 mg to 12 mg produced only 1.4 additional percentage points (from 22.8% to 24.2%).^[1] Each dose doubling yielded less additional weight loss while side effect rates continued to climb linearly. This within-drug plateau suggests a ceiling effect that is partly independent of receptor number.

Similarly, tirzepatide's SURMOUNT-1 data showed 15.0% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, a clear flattening of the dose-response curve at the highest dose.^[3]

The Economic Dimension

The diminishing returns question has direct economic implications. If adding a third receptor target increases manufacturing complexity, extends development timelines, and produces only 3 percentage points of additional weight loss, the cost-effectiveness calculation becomes challenging. Payers and health systems must weigh whether 24% weight loss from a more expensive triple agonist justifies the premium over 21% from an established dual agonist or 15% from a generic GLP-1 agonist.

This economic pressure may ultimately define the practical ceiling of multi-agonism more firmly than biology. If the incremental clinical benefit of each additional receptor target does not justify incremental cost, the market may settle on dual agonism as the optimal balance of efficacy, safety, and economics, even if triple and quadruple agonists are technically superior in clinical trials.

The Regulatory Complexity of Multi-Agonism

Multi-agonist peptides present unique regulatory challenges. With a single-target drug, regulators can evaluate mechanism, efficacy, and safety in a relatively straightforward framework. With a dual or triple agonist, each receptor axis has its own dose-response, its own safety signals, and its own contribution to efficacy. Disentangling which receptor is responsible for which clinical effect is difficult.

This complexity is visible in survodutide's Phase 2 MASH trial, where the 6.0 mg dose performed worse than 4.8 mg for the primary endpoint. The most likely explanation is higher dropout from GI side effects at the top dose, but regulators must consider whether the inverted dose-response reflects a genuine pharmacological ceiling or a trial design artifact. For single-target drugs, an inverted dose-response curve is a red flag. For multi-agonists, where each receptor component has its own saturation point, it may be expected.

The FDA has not yet approved any dual or triple GLP-1-based agonist specifically for MASH. Tirzepatide is approved for obesity and type 2 diabetes, not for its dual agonism per se. Whether regulators will require multi-agonist-specific safety evaluations, such as studies isolating each receptor component's contribution, remains unclear. This regulatory uncertainty adds timeline risk to triple agonist development programs.

What Comes After Triple Agonism?

The field is already exploring beyond three receptors. Quadruple agonists incorporating amylin receptor activation, NPY2R agonism, or cannabinoid receptor-1 inverse agonism are in preclinical development. Each addition could theoretically push the weight loss ceiling higher.

But the pattern of diminishing returns suggests a different strategic direction may prove more productive: rather than adding more receptor targets to a single molecule, combining proven single- and dual-agonist drugs with agents targeting completely orthogonal pathways. For example, combining tirzepatide with a myostatin inhibitor to preserve lean mass, or combining semaglutide with a bimagrumab-like agent that shifts the ratio of fat to muscle loss. This combinatorial approach avoids the molecular complexity of packing four or five receptor agonism into one peptide while still engaging multiple metabolic pathways.

The most honest assessment of multi-agonism's future: the technology works, each receptor addition produces real and measurable benefit, but the increments are shrinking, the side effects are growing, and the manufacturing complexity is increasing. The question is not whether a quadruple agonist will outperform a triple agonist in a clinical trial. It probably will, marginally. The question is whether that margin justifies the cost, the complexity, and the adverse event burden.

The Bottom Line

The trajectory from single (semaglutide, 15%) to dual (tirzepatide, 21%) to triple (retatrutide, 24%) receptor agonism shows clear efficacy gains, but the increments are shrinking. Each added receptor delivers less additional weight loss than the last, while gastrointestinal adverse events and discontinuation rates increase. The specific receptor combination matters as much as the number of targets, as survodutide's dual GLP-1/glucagon agonism produces less weight loss than tirzepatide's GLP-1/GIP approach despite activating the same number of receptors. The practical ceiling of multi-agonism may be determined more by tolerability limits than by pharmacological efficacy, and different clinical outcomes (liver fat vs. weight vs. cardiovascular risk) have different ceilings.

Frequently Asked Questions

What is multi-agonism in obesity treatment?

Multi-agonism refers to drugs that simultaneously activate multiple hormone receptors in a single molecule. In obesity treatment, this means peptides that combine GLP-1 receptor activation (appetite suppression) with GIP receptor activation (tirzepatide), glucagon receptor activation (survodutide), or both (retatrutide). Each additional receptor target adds a distinct metabolic pathway. The approach has produced escalating weight loss: 15% with semaglutide (single), 21% with tirzepatide (dual), and 24% with retatrutide (triple).

Is retatrutide better than tirzepatide for weight loss?

In Phase 2 data, retatrutide (triple GLP-1/GIP/glucagon agonist) produced 24.2% mean weight loss at 48 weeks, compared to tirzepatide's 20.9% at 72 weeks in SURMOUNT-1 (Jastreboff et al., NEJM, 2022 and 2023). A 2025 Bayesian meta-analysis found retatrutide was superior for achieving 15% or greater weight loss (odds ratio 54.6), though mean weight reduction was similar to dual agonists (Sinha et al., Obesity, 2025). Direct head-to-head trials have not been conducted.

What are the side effects of triple agonist peptides?

Triple agonist peptides like retatrutide cause gastrointestinal side effects similar to single and dual agonists but at higher rates. In the Phase 2 trial, retatrutide at the 12 mg dose caused nausea (26%), diarrhea (22%), and vomiting (17%), with 12-18% discontinuation rates at the two highest doses (Jastreboff et al., NEJM, 2023). Increased heart rate was also observed. The safety profile reflects the combined effects of three receptor targets rather than a single pathway.

Why does survodutide produce less weight loss than tirzepatide?

Despite both being dual agonists, survodutide (GLP-1/glucagon, 14.9% weight loss) underperforms tirzepatide (GLP-1/GIP, 20.9%). The most likely explanation is that GIP receptor activation contributes more to appetite-driven weight loss than glucagon receptor activation, which primarily increases hepatic energy expenditure. Survodutide's glucagon component provides stronger liver fat reduction (62% MASH improvement), demonstrating that the "best" second receptor depends on the target disease, not just the number of receptors (le Roux et al., Lancet D&E, 2024).

Is there a maximum limit to how much weight these drugs can produce?

A physiological ceiling likely exists. Appetite suppression cannot reduce food intake below survival minimums. Energy expenditure increases from glucagon agonism are modest in humans. Tolerability limits prevent further dose escalation as gastrointestinal side effects increase with each receptor target. The incremental gains from adding receptors are shrinking: +6 points from single to dual, +3 from dual to triple. The practical limit is likely near 25-30% weight loss before side effects or physiological constraints dominate.

What comes after triple agonist peptides for obesity?

Quadruple agonists (adding amylin, NPY2R, or other targets) are in preclinical development. An alternative approach gaining traction is combination therapy: pairing proven dual agonists with drugs targeting orthogonal pathways, such as myostatin inhibitors for lean mass preservation or SGLT2 inhibitors for metabolic benefits. This avoids the molecular complexity of packing more receptor targets into one peptide while still engaging multiple metabolic pathways.